Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Current Deferred Revenue (2022 - 2025)

IceCure Medical has reported Current Deferred Revenue over the past 4 years, most recently at $255000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 23.65% year-over-year to $255000.0; the TTM value through Dec 2025 reached $255000.0, down 23.65%, while the annual FY2025 figure was $255000.0, 23.65% down from the prior year.
  • Current Deferred Revenue was $255000.0 for Q4 2025 at IceCure Medical, down from $334000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $646000.0 in Q4 2022 and bottomed at $187000.0 in Q4 2023.
  • The 4-year median for Current Deferred Revenue is $294500.0 (2024), against an average of $355500.0.
  • Year-over-year, Current Deferred Revenue crashed 71.05% in 2023 and then soared 78.61% in 2024.
  • Over 4 years, Current Deferred Revenue stood at $646000.0 in 2022, then crashed by 71.05% to $187000.0 in 2023, then soared by 78.61% to $334000.0 in 2024, then fell by 23.65% to $255000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $255000.0 (Q4 2025), $334000.0 (Q4 2024), and $187000.0 (Q4 2023) per Business Quant data.